Table 2.

Univariate and multivariate logistic regression analyses of treatment response (based on the overall response rate) and clinical characteristics in the total population (N = 28)

Clinical characteristics		Response/total, (N)	Univariate analysis		Multivariate analysis
			Odds ratio (95% CI)	P	Odds ratio (95% CI)	P
Sex	Male	6/14	ref
	Female	5/14	0.7 (0.2, 3.4)	0.70
BMI	Normal/underweight	7/16	ref
	Overweight/obese	4/12	0.6 (0.1, 3.0)	0.58	0.8 (0.1, 6.1)	0.84
Smoking status	Never-smoker	7/20	ref
	Ever-smoker	4/8	1.9 (0.4, 9.8)	0.47
Antibiotics	Yes	1/3	0.8 (0.1, 9.4)	0.82
	No	10/25	ref
PPIs	Yes	3/5	2.8 (0.4, 20.5)	0.31
	No	8/23	ref
Laxatives	Yes	2/8	0.4 (0.1, 2.5)	0.34
	No	9/20	ref
Prebiotics/Prebiotics	Yes	4/8	1.9 (0.4, 9.8)	0.47	1.8 (0.2, 14.2)	0.58
	No	7/20	ref
Supplement	Yes	3/4	5.6 (0.5, 63.3)	0.16
	No	12/24	ref
Lung/pleural metastasis	Yes	5/17	0.3 (0.1, 1.7)	0.19	0.8 (0.1, 6.3)	0.84
	No	6/11	ref
Brain metastasis	Yes	3/5	2.8 (0.4, 20.4)	0.31	1.5 (0.1, 18.1)	0.75
	No	8/23	ref
Albumin	< 3.2 g/dL	1/12	ref
	≥ 3.2 g/dL	10/16	18.3 (1.9, 179.9)	0.01	15.6 (1.3, 182.0)	0.03
Cohort	EGFR-WT	1/13	ref
	EGFR-mutant	10/15	23.9 (2.4, 240.6)	0.0007	not available
Shannon diversity index		11/28	1.2 (0.4, 3.8)	0.77	1.0 (0.3, 4.2)	0.97

BMI Body mass index, EGFR Epidermal growth factor receptor, PPI Proton pump inhibitor, WT Wild-type